[go: up one dir, main page]

HUP0103344A3 - Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp), process for their preparation and pharmaceutical compositions containing them - Google Patents

Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp), process for their preparation and pharmaceutical compositions containing them

Info

Publication number
HUP0103344A3
HUP0103344A3 HU0103344A HUP0103344A HUP0103344A3 HU P0103344 A3 HUP0103344 A3 HU P0103344A3 HU 0103344 A HU0103344 A HU 0103344A HU P0103344 A HUP0103344 A HU P0103344A HU P0103344 A3 HUP0103344 A3 HU P0103344A3
Authority
HU
Hungary
Prior art keywords
arylpiperazines
mmp
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0103344A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUP0103344A2 publication Critical patent/HUP0103344A2/hu
Publication of HUP0103344A3 publication Critical patent/HUP0103344A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0103344A 1998-08-31 1999-08-25 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp), process for their preparation and pharmaceutical compositions containing them HUP0103344A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98402144 1998-08-31
EP99401351 1999-06-04
PCT/GB1999/002801 WO2000012478A1 (en) 1998-08-31 1999-08-25 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)

Publications (2)

Publication Number Publication Date
HUP0103344A2 HUP0103344A2 (hu) 2002-02-28
HUP0103344A3 true HUP0103344A3 (en) 2002-03-28

Family

ID=26151689

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103344A HUP0103344A3 (en) 1998-08-31 1999-08-25 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp), process for their preparation and pharmaceutical compositions containing them

Country Status (32)

Country Link
US (2) US6734184B1 (hu)
EP (1) EP1109787B1 (hu)
JP (1) JP4776778B2 (hu)
KR (1) KR100771454B1 (hu)
CN (1) CN1183119C (hu)
AT (1) ATE326448T1 (hu)
AU (1) AU764367B2 (hu)
BG (1) BG65426B1 (hu)
BR (1) BR9913255A (hu)
CA (1) CA2339761C (hu)
CY (1) CY1106139T1 (hu)
DE (1) DE69931375T2 (hu)
DK (1) DK1109787T3 (hu)
EE (1) EE05005B1 (hu)
ES (1) ES2263284T3 (hu)
GB (1) GB9919776D0 (hu)
HU (1) HUP0103344A3 (hu)
ID (1) ID28786A (hu)
IL (2) IL141410A0 (hu)
IS (1) IS5849A (hu)
MX (1) MXPA01001847A (hu)
MY (1) MY129409A (hu)
NO (1) NO321478B1 (hu)
NZ (2) NZ509730A (hu)
PL (1) PL199894B1 (hu)
PT (1) PT1109787E (hu)
RU (1) RU2220967C2 (hu)
SI (1) SI1109787T1 (hu)
SK (1) SK286658B6 (hu)
TR (1) TR200100605T2 (hu)
TW (1) TWI240722B (hu)
WO (1) WO2000012478A1 (hu)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1187811B1 (en) * 1999-06-04 2007-03-07 AstraZeneca AB Inhibitors of metalloproteinases
EP1261595A1 (en) * 2000-02-21 2002-12-04 AstraZeneca AB Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
EP1274697A1 (en) * 2000-02-21 2003-01-15 AstraZeneca AB Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
UA73155C2 (en) * 2000-02-21 2005-06-15 Astrazeneca Ab Substituted by piperidine and piperazine n-hydroxyformamides as metalloproteinase inhibitors
AU5652001A (en) 2000-05-15 2001-11-26 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO2001087844A1 (en) * 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
AU2001267468A1 (en) * 2000-05-25 2001-12-03 Smithkline Beecham P.L.C. Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
KR20040013090A (ko) 2001-07-02 2004-02-11 아스트라제네카 아베 케모킨 수용체 활성의 조절자로서 유용한 피페리딘 유도체
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
GB0119473D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Compounds
GB0119474D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
ATE420068T1 (de) 2001-09-07 2009-01-15 Kaken Pharma Co Ltd Reverse hydroxamsäurederivate
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
WO2003040103A1 (en) * 2001-11-02 2003-05-15 Bristol-Myers Squibb Company β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
DE60321775D1 (de) 2002-04-03 2008-08-07 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
GB0216383D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Compounds
GB0216379D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Compounds
GB0216382D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221250D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US7465719B2 (en) 2003-01-17 2008-12-16 Topotarget Uk Limited Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
ATE411303T1 (de) * 2003-06-19 2008-10-15 Ucb Pharma Sa Hydroxamatsulfonamide als inhibitoren von cd23- shedding
SE0301922D0 (sv) * 2003-06-27 2003-06-27 Astrazeneca Ab Novel compounds
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
GB0427403D0 (en) * 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
BRPI0517032A (pt) * 2004-12-16 2008-09-30 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
CA2589367C (en) * 2004-12-21 2015-02-03 Laboratoires Serono S.A. Sulfonyl amino cyclic derivatives and use thereof
FR2885616B1 (fr) * 2005-05-12 2007-06-22 Servier Lab Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2885615B1 (fr) * 2005-05-12 2007-06-22 Servier Lab Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2397418T3 (es) 2005-07-21 2013-03-06 Astrazeneca Ab Derivados de piperidina
PL1951674T3 (pl) * 2005-10-26 2012-04-30 Merck Serono Sa Pochodne sulfonamidowe i ich zastosowania do modulowania metaloproteinaz
US7998964B2 (en) * 2005-11-24 2011-08-16 Merck Serono S.A. N-hydroxyamide derivatives and use thereof
PT1976828T (pt) 2005-12-29 2017-03-10 Celtaxsys Inc Derivados de diamina como inibidores de leucotrieno a4 hidrolase
DK2597084T3 (en) 2010-07-08 2016-08-15 Kaken Pharma Co Ltd N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICINAL CONTAINING SAME
EP2953932B1 (en) 2013-02-06 2017-03-01 Merck Patent GmbH Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
CA2905340C (en) 2013-03-12 2022-05-31 Celtaxsys, Inc. Low dose oral formulations of acebilustat
RU2696559C2 (ru) 2013-03-14 2019-08-05 Селтакссис, Инк. Ингибиторы лейкотриен а4-гидролазы
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
CA2906086A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
EP3801559B1 (en) 2018-05-31 2025-01-01 Celltaxis, LLC Method of reducing pulmonary exacerbations in respiratory disease patients
CA3102683A1 (en) 2018-06-07 2019-12-12 Idorsia Pharmaceuticals Ltd Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis
US12286401B2 (en) 2018-07-31 2025-04-29 The Trustees Of The University Of Pennsylvania Small molecules that sensitize HIV-1 infected cells to antibody dependent cellular cytotoxicity
WO2020070239A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
US12539294B2 (en) 2019-12-04 2026-02-03 Idorsia Pharmaceuticals Ltd Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3532340A (en) * 1967-08-11 1970-10-06 Vincent Nardiello Spring type abdominal exercising device
ES426195A1 (es) * 1973-05-18 1976-07-01 Mega Produc U Verpackungsentwi Perfeccionamientos en aparatos para entrenamiento muscular.
US4480831A (en) * 1982-03-12 1984-11-06 Mueller Deinhardt Friedhelm Exercise hoop having a counter
BE897714A (nl) * 1983-09-09 1984-01-02 Nelissen Koenraad Ring met elastiek en handvat
US4607625A (en) * 1985-01-10 1986-08-26 Schenck Robert R Dynamic traction device
US4724827A (en) * 1985-01-10 1988-02-16 Schenck Robert R Dynamic traction device
GB9411598D0 (en) * 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
US5674162A (en) * 1995-06-07 1997-10-07 Ellingson; Richard L. Biomechanical stabilizer apparatus and methods for strengthening unstable joints and improving muscle coordination
ES2217425T3 (es) * 1996-08-07 2004-11-01 Darwin Discovery Limited Derivados del acido hidroxamico y del acido carboxilico con actividad inhibitoria de la mmp y del tnf.
WO1998016514A1 (en) * 1996-10-16 1998-04-23 American Cyanamid Company Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
WO1998027069A1 (en) * 1996-12-17 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf
TR199901765T2 (xx) 1997-01-23 1999-10-21 F.Hoffmann-La Roche Ag S�lfomid-metalloproteaz inhibit�rleri
ZA98376B (en) 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
US6482827B1 (en) 1997-07-10 2002-11-19 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
WO1999002510A1 (en) 1997-07-10 1999-01-21 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
BR9811573A (pt) * 1997-07-31 2000-09-19 Elan Pharm Inc Compostos de benzila que inibem a adesão de leucócitos mediada por vla-4
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6130220A (en) 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
WO1999038843A1 (en) 1998-01-30 1999-08-05 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
EP1087937A1 (en) * 1998-06-17 2001-04-04 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
AU5634999A (en) 1998-08-29 2000-03-21 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as proteinase inhibitors

Also Published As

Publication number Publication date
BG105369A (en) 2001-12-29
SI1109787T1 (sl) 2006-10-31
MXPA01001847A (es) 2002-04-08
CA2339761C (en) 2010-10-12
HK1036060A1 (en) 2001-12-21
NZ524921A (en) 2004-10-29
IL141410A (en) 2007-06-03
AU5524799A (en) 2000-03-21
PL346344A1 (en) 2002-02-11
US7342020B2 (en) 2008-03-11
PT1109787E (pt) 2006-09-29
BG65426B1 (bg) 2008-07-31
EE200100106A (et) 2002-06-17
EP1109787A1 (en) 2001-06-27
EE05005B1 (et) 2008-04-15
TR200100605T2 (tr) 2001-08-21
NO321478B1 (no) 2006-05-15
US6734184B1 (en) 2004-05-11
ID28786A (id) 2001-07-05
AU764367B2 (en) 2003-08-14
HUP0103344A2 (hu) 2002-02-28
CA2339761A1 (en) 2000-03-09
NZ509730A (en) 2003-05-30
CN1183119C (zh) 2005-01-05
CY1106139T1 (el) 2011-06-08
KR20010073000A (ko) 2001-07-31
EP1109787B1 (en) 2006-05-17
DK1109787T3 (da) 2006-08-21
JP4776778B2 (ja) 2011-09-21
SK286658B6 (sk) 2009-03-05
ATE326448T1 (de) 2006-06-15
KR100771454B1 (ko) 2007-10-31
NO20011023L (no) 2001-04-25
PL199894B1 (pl) 2008-11-28
IS5849A (is) 2001-02-16
MY129409A (en) 2007-03-30
SK2702001A3 (en) 2001-08-06
TWI240722B (en) 2005-10-01
ES2263284T3 (es) 2006-12-01
NO20011023D0 (no) 2001-02-28
US20040171641A1 (en) 2004-09-02
DE69931375D1 (de) 2006-06-22
WO2000012478A1 (en) 2000-03-09
IL141410A0 (en) 2002-03-10
CN1324347A (zh) 2001-11-28
JP2002523493A (ja) 2002-07-30
RU2220967C2 (ru) 2004-01-10
DE69931375T2 (de) 2007-05-24
GB9919776D0 (en) 1999-10-27
BR9913255A (pt) 2001-05-22

Similar Documents

Publication Publication Date Title
HUP0103344A3 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp), process for their preparation and pharmaceutical compositions containing them
HUP0101176A3 (en) Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them
HUP0200347A2 (en) N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use
HUP0203122A3 (en) Fab i inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
HUP0200355A2 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
HUP0204519A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing them and process for their preparations
HUP0301577A3 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
HUP0103376A3 (en) New 3-aryl-2-hydroxypropionic acid derivative, pharmaceutical compositions containing it, process for their preparation and their use
HUP0103283A3 (en) Pyrazinone protease inhibitors, pharmaceutical compositions containing them and use of the compounds
HUP0203136A3 (en) Piperazine compounds, process for their preparation, pharmaceutical compositions containing them and their use
HUP0400194A3 (en) Imidazolidindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
HUP0103851A3 (en) Factor viia inhibitors, process for their preparation, their use and pharmaceutical compositions comprising thereof
HUP0103333A3 (en) Pyrroloindoles, pyridoindoles and azepinoindiles as 5-ht2c agonists, process for their preparation and pharmaceutical compositions containing them
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
HUP0102766A3 (en) Aminomethylcarboxylic acid derivatives, their pharmaceutical use and pharmaceutical compositions comprising them
HUP0102512A3 (en) Bridged indenopyrrolocarbazoles, process for their preparation, pharmaceutical compositions containing them and their use
IL140897A0 (en) Benzocycloheptene derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
AU7294098A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
IL138969A0 (en) Anthranilic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0301240A3 (en) Pyridazine compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors and pharmaceutical compositions containing them
HUP0102215A3 (en) Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation
IL143577A0 (en) Piperazine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0202934A3 (en) Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof
HUP0100277A3 (en) 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as metalloproteinase inhibitors, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees